A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
for Moderately to Severely Active Crohns Disease
52 locations incl. Glendale
Sponsor: Hoffmann-La Roche
Sex: All·Age: 16 - 80
Code: NCT06819891·Phase 3·Recruiting·Listed Feb 2025